| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, California 92093
We examined the importance of the Na+,K+-ATPase in cisplatin (DDP) accumulation in 2008 human ovarian carcinoma cells and describe changes in the Na+,K+-ATPase in DDP-resistant cells with DDP accumulation defects. Approximately 50% of DDP accumulation was inhibitable by ouabain. DDP accumulation into 2008 cells could be maximally inhibited when cells were preincubated with ouabain for 1 h prior to DDP exposure. The half-maximal inhibition was obtained with 0.13 µM ouabain. Similar inhibition of DDP accumulation was obtained when the Na+,K+-ATPase was blocked by ATP depletion or by incubating cells in K+-free medium. This same percentage of DDP accumulation was Na+ dependent and varied directly with Na+ concentration. These effects on DDP accumulation could be detected as early as 1 min after the imposition of 0-trans conditions, strongly suggesting that the inhibition was due to modulation of a drug influx step. The Na+,K+-ATPase in 2008/DDP cells had a similar KD for ouabain binding and 36% less Na+,K+-ATPase molecules/mg of protein than 2008 cells. 2008/DDP cells were 2.3 ± 0.2 (SE, n = 3) fold cross-resistant to ouabain in a continuous exposure clonogenic assay. Despite these changes in the Na+,K+-ATPase, the net basal Na+,K+-ATPase activity was the same in sensitive and DDP-resistant cells as determined by ouabain-inhibitable 86Rb+ influx. The basal Na+ levels were also similar in the sensitive and resistant cells. These data suggest that DDP accumulation is partially Na+ dependent and that, therefore, the Na+,K+-ATPase which maintains the Na+ gradient may play an important role in determining how much DDP enters cells. Whether there is a causal link between the changes in the Na+,K+-ATPase in DDP-resistant cells and their DDP accumulation defect is not yet known.
1 Supported by Grant CA-23100 from the National Cancer Institute, Grant CH-417 from the American Cancer Society, and Grant 100-R107 from Bristol-Myers, Co. This work was conducted in part by the Clayton Foundation for Research, California Division. P. A. A. is a Clayton Foundation Investigator.
2 To whom requests for reprints should be addressed, at Georgetown University, 4 Research Court, Rockville, MD 20850.
Received 10/25/90. Accepted 5/ 6/91.
This article has been cited by other articles:
![]() |
L.-S. Wang, K.-C. Chow, Y.-C. Lien, K.-T. Kuo, and W.-Y. Li Prognostic significance of nm23-H1 expression in esophageal squamous cell carcinoma Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 419 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Katano, R. Safaei, G. Samimi, A. Holzer, M. Tomioka, M. Goodman, and S. B. Howell Confocal Microscopic Analysis of the Interaction between Cisplatin and the Copper Transporter ATP7B in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 1, 2004; 10(13): 4578 - 4588. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Samimi, N. M. Varki, S. Wilczynski, R. Safaei, D. S. Alberts, and S. B. Howell Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients Clin. Cancer Res., December 1, 2003; 9(16): 5853 - 5859. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Katano, A. Kondo, R. Safaei, A. Holzer, G. Samimi, M. Mishima, Y.-M. Kuo, M. Rochdi, and S. B. Howell Acquisition of Resistance to Cisplatin Is Accompanied by Changes in the Cellular Pharmacology of Copper Cancer Res., November 15, 2002; 62(22): 6559 - 6565. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lin, T. Okuda, A. Holzer, and S. B. Howell The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae Mol. Pharmacol., November 1, 2002; 62(5): 1154 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Brouillard, D. Tondelier, A. Edelman, and M. Baudouin-Legros Drug Resistance Induced by Ouabain via the Stimulation of MDR1 Gene Expression in Human Carcinomatous Pulmonary Cells Cancer Res., February 1, 2001; 61(4): 1693 - 1698. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |